top of page

egSEQ Comprehensive Oncology Panel is a hybridisation-based targeted sequencing panel covering >600 genes, as well as important MSI and fusion sites related to solid tumours and targeted therapies, allowing accurate, comprehensive and cost-effective analysis of all types of mutations, including SNVs, InDels, CNVs, and rearrangements. egSEQ Comprehensive Oncology Panel provides a comprehensive approach to analysing actionable biomarkers relevant to oncological diagnosis, prognosis, and therapy with tissue, FFPE and cfDNA samples.



  • Including important genes and fusion intron regions.

  • TMB and MSI for immunotherapy evaluation.

  • Market-leading capture efficiency of up to 75% and exceptional uniformity with 20X > 99%.

  • Available with UMI adapter for more precise analysis.



  • Targeted therapy and concomitant diagnosis.

  • Mutation analysis of tumour-related genes.

  • Suitable for patients with existing solid tumours and those with a family history.

egSEQ Comprehensive Oncology Panel

  • Product Code Specification 
    EG1312S 16 rxn
    EG1312 96 rxn


    User Guide

    Product Information Sheet

    Safety Data Sheet (EG1312S)

    Safety Data Sheet (EG1312)

bottom of page